small molecule

YONDELIS

TRABECTEDIN

Loss of exclusivityJuly 2028latest FDA-listed patent expiry
CompanyJANSSEN PRODUCTS LP

Drug detail

Brand nameYONDELIS
Active ingredientTRABECTEDIN
Strength1MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusRX

Listed patents

PatentExpiresType
8895557*PEDJuly 2028
8895557January 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

YONDELIS patent cliff — loss of exclusivity July 2028 | CliffBio